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Abstract
Background: Sentinel site surveillance of antimalarials by in-vivo therapeutic efficacy studies in
Zambia is one of the key activities ear-marked for monitoring and evaluation. The studies are
conducted annually in order to provide timely and reliable information on the status of the
recommended regimens for malaria case management. The findings of the therapeutic efficacy of
an artemisinin-based combination therapy of pediatric artemether-lumefantrine (Coartesiane®) are
reported.
Method: The design is a simple, one-arm, prospective evaluation of the clinical and parasitological
response to directly observed treatment for uncomplicated malaria. The study was conducted in
sentinel sites using the WHO standardized protocol for the assessment of therapeutic efficacy of
antimalarial drugs (WHO 2000) in children under five years of age, weighing less than 10 Kg. The
study was conducted at two clinics, one in Chongwe (Lusaka Province) and Chipata (Eastern
Province). The 28-day follow-up period was used coupled with PCR genotyping for MSP1 and MSP2
in order to differentiate recrudescence from re-infections for parasites that appeared after Day 14.
Results:  91/111 children enrolled in the study, were successfully followed up. Artemether-
lumefantrine (Coartesiane®) was found to produce significant gametocyte reduction. The Adequate
Clinical and Parasitological Response (ACPR) was found to be 100% (95% CI 96.0;100).
Conclusion: Coartesiane® was effective in treating uncomplicated malaria in Zambian children
weighing less than 10 kg, an age group normally excluded from taking the tablet formulation of
artemether-lumefantrine (Coartem®).
Background
The malaria situation analysis in Zambia shows that
malaria is the leading cause of mortality and morbidity,
and the disease burden is worse in the biologically vulner-
able children, under five years of age, and in pregnant
women [1]. The development of drug resistance in Zam-
bia has had a major impact on the success of malaria con-
trol. The country has experienced major treatment failures
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to chloroquine and sulphadoxine/pyrimethamine (SP),
with recorded treatment failures for SP as high as 32.6%
in certain parts of the country by early 2003 [2]. After the
documentation of chloroquine resistance in 1983, the
outpatient department (OPD) cases increased from 167
cases per thousand population to 428 cases per thousand
population in 2003 [3]. The public health impact of drug
resistance led to an increase in the disease prevalence
rates, under five mortality rates and a corresponding
increase in case fatality rates. This was evidenced by an
upward surge in all epidemiological indicators of the
malaria disease.
The assessment and monitoring of antimalarial therapeu-
tic efficacy is key to the provision of sound evidence for
policy decisions making regarding which antimalarials
can be adopted for malaria case management. The
National Malaria Control Centre has over time developed
a consistent system for sentinel site surveillance of the
therapeutic efficacy of antimalarial drugs. These studies
have played a major role in guiding the country's decision
to move from monotherapies to Artemisinin-Based Com-
bination Therapies (ACTs).
The use of combination therapy is expected to have a pos-
itive impact on malaria transmission by lowering the rates
of gametocytaemia after treatment. Artemisinin deriva-
tives are advocated for use in antimalarial combination
therapy because they quickly reduce the level of parasitae-
mia and hence the parasite pool from which resistant P.
falciparum strains may arise [4].
But, as the new drug policy outlines, SP is the current rec-
ommended drug for intermittent presumptive treatment
for malaria in pregnancy and for children weighing less
than 10 Kg. These two groups were excluded from using
the tablet formulation of artemether-lumefantrine (Coar-
tem®), because there was insufficient safety and efficacy
data at the time of the policy change.
The therapeutic efficacy of Coartesiane®  in treating
uncomplicated Plasmodium falciparum malaria in children
was assessed. The findings will be useful in providing evi-
dence on the possible options for children who currently
are being exposed to the ineffective SP.
Methodology
Study design
The study was an open label one arm prospective evalua-
tion of the therapeutic efficacy of antimalarials in design.
It was conducted between March to May 2005 in two sen-
tinel sites, Chongwe and Chipata.
Study population and sample size
The patients included were children under five years of
age, weighing less than 10 Kg (the minimum weight
admissible for Coartem®). Other criteria used for inclu-
sion were: absence of severe malnutrition, mono-infec-
tion with P. falciparum , with a parasitaemia in the range
of 2,000 to 200,000 asexual parasites per micro litre of
blood, absence of severe malaria or danger signs, axillary
temperature ≥ 37.5°C at visit, absence of other febrile
conditions, ability to come for follow-up visit and
informed consent from parent or guardian.
The classical statistical methods for determining sample
size based on an expected proportion of treatment failures
was used, with a 95% confidence level and a precision of
10%. The failure rates were expected to be lower than
15%, so a minimum of 50 patients had to be enrolled at
each site.
Parasitological examination
Two thick films were prepared before treatment on Day 0,
and on Days 1, 2, 3, 7, 14, 21 and 28 including any other
day that the patient was brought to the clinic before the
next scheduled visit. One thick film was used for rapid
staining (10–15 minutes in 10% Giemsa stain) while the
second film was for slow staining (30–45 minutes in 3%
Giemsa stain). The quick stain was used for initial screen-
ing for the presence of parasites, while the second blood
smear was used to calculate parasite density. Parasitaemia
(per microlitre) = number of parasites × 8,000/number of
leucocytes counted.
Two laboratory technicians were engaged in the study and
both read through all the slides independently to assure
quality. All the slides for the patients on the study were
collected and used in quality control by an independent
laboratory.
Treatment and follow-up
The study followed the standard World Health Organiza-
tion (WHO) Protocol for the Assessment of Therapeutic Effi-
cacy of Antimalarial Drugs for Uncomplicated Plasmodium
falciparum malaria adapted to the Zambian situation to
include studies with artemisinin-based combination ther-
apy. The 28-day follow-up period was used.
On enrolment day, Day 0, a brief history of each child was
obtained, the patient was weighed and the axillary tem-
perature was recorded. The patient was then sent for labo-
ratory examination to confirm malaria diagnosis and also
to identify if parasitaemia was adequate for enrolment.
Upon fulfillment of all inclusion criteria, consent was
obtained from the caretaker and the child was enrolled on
the study.Malaria Journal 2006, 5:75 http://www.malariajournal.com/content/5/1/75
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Coartesiane® is an oral suspension of artemether (180 mg/
60 ml) and lumefantrine (1080 mg/60 ml) indicated for
the treatment of malaria in children. It is presented in a
yellow powder which can be diluted with water to form a
60 ml suspension. The dosing schedule is based on body
weight and it is to be taken once a day for three days. The
drug is manufactured by Dafra Pharma nv/sa. The drug is
registered in Zambia for use in children for the treatment
of uncomplicated malaria and is being used in the private
sector.
All medication was given under the supervision of the
study team. Patients were observed for a few minutes after
administering the study drug to ensure that they did not
vomit. Any child who vomited had the dose re-adminis-
tered but if vomiting persisted, the child was dropped
from the study and referred for further management. A
photograph of the child was taken as an identification
tool on follow-up days and also as an incentive upon
completion of the study.
Follow-ups were scheduled for Days 2, 3, 7, 14, 21 and 28
plus any other day that the child was taken to the clinic on
unscheduled day. On each of these days clinical and par-
asitological assessments were performed. The community
health worker ensured the directions to the home of the
patient were well written for ease of tracking of patients.
Filter paper samples of blood were taken on Day 0 and
any other day when the parasites first reappeared in the
blood of the patient. Polymerase Chain Reaction (PCR)
genotyping for MSP1 and MSP2 was done to differentiate
recrudescence from re-infections. DNA was extracted from
the filter papers and analysed using standard methods as
described elsewhere [5,6]. A recrudescent infection was
defined if the allelic bands of the subsequent infection
were similar to the Day 0 pattern. However, a reinfection
was defined if the allelic bands for the subsequent infec-
tion were different from the Day 0 bands.
Children were withdrawn from the study if the patient
developed any signs of severe or complicated malaria or
any of the general danger signs during the follow-up
period; he/she was given the first dose of parenteral qui-
nine and taken urgently to the appropriate health facility.
For ethical reasons, all children with parasitaemia on Day
28, irrespective of symptoms were treated with the alter-
native antimalarial drug (oral quinine) at the end of the
follow-up period.
Incentives
Incentives were given to the caretakers as a way to moti-
vate them not to miss a scheduled visit to the study site. A
1 Kg packet of sugar was given to each patient on Day 3, a
bar of laundry soap on Day 7 and a packet of salt on Day
14 and a photograph of the child on Day 28. Any child,
who dropped from the study before Day 28, received the
photo on the last day of being on the study. Sweets were
given to the children as an incentive for the number of fin-
ger pricks they get on the study.
Data collection
The data was recorded depending on the day of the study.
The screening Log sheet was kept in the laboratory and
this had serial numbers and information of all the
patients screened for the study irrespective of their parasi-
taemia and clinical condition. The Case enrolment form
was used for the patient's case history and it also con-
tained clinical and parasitological data for Day 0. The case
record form was used to record the patients' study
number, directions to home, study drug, and all the clini-
cal and parasitological data for Day 0 to Day 28, and the
final classification of therapeutic response.
Classification of therapeutic response
Three categories of therapeutic response, namely Early
Treatment Failure (ETF), Late Treatment Failure (LTF) and
Adequate Clinical and Parasitological Response (ACPR)
were used. This is based on the WHO classification system
[7]. At all times during the study, the patient welfare took
priority and all the procedures were done in line with the
standard guidelines of good practice,
The statistical procedure adapted for the interpretation of
the results allowed testing the hypothesis that the propor-
tion of treatment failures was above a certain level in the
study area, and, therefore, a decision to change is deemed
necessary.
Collaboration with the major institutions in the country
ensured the quality of study results. The study team mem-
bers came from the National Malaria Control Centre,
Tropical Diseases Research Centre, Macha Malaria
Research Institute, University Teaching Hospital and
Chainama Hills College of Health Sciences and District
Health Management teams (DHMTs).
Ethical considerations
The study was conducted in accordance with the stand-
ards of good clinical practice.
Ethical clearance was sought from The Tropical Disease
Research Centre Institutional Research Committee
(#00002911). The study was also cleared by the Central
Board of Health Director General's Office and the partici-
pating districts. All participants were enrolled after a writ-
ten consent was obtained from the caretaker. The
participants also received incentives to help them during
the long follow up days. All information obtained in the
study was treated with the confidentiality it deserved.Malaria Journal 2006, 5:75 http://www.malariajournal.com/content/5/1/75
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Results
Out of the 111 patients enrolled in the two sites, 91 were
successfully followed up. Baseline characteristics of partic-
ipants are outlined in Table 1. The ACPR after 28 days fol-
low up was 100% (95% confidence interval 96.0% to
100%). There were no early treatment failures reported
and all the analysable LCF and LPF were due to re-infec-
tions. The gametocytes that were reported to be present on
Day 0 (368 per microlitre of blood) and Day 2 (336 per
microlitre of blood) reduced significantly by Day 7 (80/µl
of blood), with none being recorded on Day 21 and Day
28. No clinically detectable drug reactions were reported
during the study period. The rate of re-infection was found
to be 37% (Chongwe) and 20.8% (Chipata), respectively
(Table 2).
Discussion
Coartesiane® was found to have excellent 28-day thera-
peutic efficacy among children weighing less than 10 Kg.
This drug has the potential of providing a viable option
for children who are not eligible to take Coartem® . There
is need, therefore, to continue to evaluate the long-term
safety profile of this drug in the younger children. The
drug had 28-day ACPR rates superior to those of SP
(100% vs 76.1%) being recorded in Zambia in children
with similar age and weight characteristics.
The study is limited in nature because it was not a rand-
omized clinical trial which would have been ideal. How-
ever, an open label was opted for because there is
sufficient data on the efficacy of the tablet formulation of
artemether-lumefantrine[8-11].
Further studies are needed to estimate the long-term safety
and pharmacological action of this pediatric formulation.
This will provide more information for countries where
the use of this drug may be contemplated. The gametocyte
clearance characteristics were similar to those, which have
been recorded with the tablet formulation of artemether-
lumefantrine [8,9]. The use of MSP genotyping to differ-
entiate re-infections from recrudescent strains has been
useful in evaluating the therapeutic efficacy of the drug.
Conclusion
Coartesiane® was very effective in treating uncomplicated
P. falciparum malaria in children weighing less than 10 Kg
in Zambia.
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